279 related articles for article (PubMed ID: 22473680)
1. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
3. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Castagna L; Magagnoli M; Balzarotti M; Sarina B; Siracusano L; Nozza A; Todisco E; Bramanti S; Mazza R; Russo F; Timofeeva I; Santoro A
Am J Hematol; 2007 Feb; 82(2):122-7. PubMed ID: 17019686
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
8. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
9. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
[TBL] [Abstract][Full Text] [Related]
10. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
11. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Musso M; Messina G; Di Renzo N; Di Carlo P; Vitolo U; Scalone R; Marcacci G; Scalzulli PR; Moscato T; Matera R; Crescimanno A; Santarone S; Orciuolo E; Merenda A; Pavone V; Pastore D; Donnarumma D; Carella AM; Ciochetto C; Cascavilla N; Mele A; Lanza F; Di Nicola M; Bonizzoni E; Pinto A
Br J Haematol; 2016 Jan; 172(1):111-21. PubMed ID: 26458240
[TBL] [Abstract][Full Text] [Related]
15. Standard therapy of advanced Hodgkin lymphoma.
Kuruvilla J
Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235
[TBL] [Abstract][Full Text] [Related]
16. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
[TBL] [Abstract][Full Text] [Related]
17. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
19. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Fermé C; Mounier N; Diviné M; Brice P; Stamatoullas A; Reman O; Voillat L; Jaubert J; Lederlin P; Colin P; Berger F; Salles G
J Clin Oncol; 2002 Jan; 20(2):467-75. PubMed ID: 11786576
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]